Michael Edward Szperka

Array ( [id] => 15432475 [patent_doc_number] => 20200030420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => METHODS OF USING A FIXED DOSE OF A CLOTTING FACTOR [patent_app_type] => utility [patent_app_number] => 16/502352 [patent_app_country] => US [patent_app_date] => 2019-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16502352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14993853 [patent_doc_number] => 20190315884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII [patent_app_type] => utility [patent_app_number] => 16/459791 [patent_app_country] => US [patent_app_date] => 2019-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16459791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038731 [patent_doc_number] => 20190330370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => COMPOSITIONS AND METHODS FOR INCREASING PROTEIN HALF-LIFE IN A SERUM [patent_app_type] => utility [patent_app_number] => 16/458872 [patent_app_country] => US [patent_app_date] => 2019-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16458872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18701352 [patent_doc_number] => 11787851 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => Optimized factor VIII gene [patent_app_type] => utility [patent_app_number] => 16/452010 [patent_app_country] => US [patent_app_date] => 2019-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 34976 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16452010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681285 [patent_doc_number] => 20200095306 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => PREVENTION OF TISSUE ISCHEMIA AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 16/443415 [patent_app_country] => US [patent_app_date] => 2019-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75342 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16443415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20372502 [patent_doc_number] => 12479926 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-25 [patent_title] => Anti-MUC1 antibody-drug conjugate [patent_app_type] => utility [patent_app_number] => 17/055323 [patent_app_country] => US [patent_app_date] => 2019-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 19 [patent_no_of_words] => 27940 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17055323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14712801 [patent_doc_number] => 20190247464 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => COMPOSITIONS AND METHODS FOR INDUCING THROMBOPOIESIS [patent_app_type] => utility [patent_app_number] => 16/392685 [patent_app_country] => US [patent_app_date] => 2019-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16392685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715715 [patent_doc_number] => 20190248921 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => TREATMENT FOR HEMORRHAGIC DISEASES BY ANTI-PROTEIN-C ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/391848 [patent_app_country] => US [patent_app_date] => 2019-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16391848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16932458 [patent_doc_number] => 20210198347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => ANTI-COMPLEMENT COMPONENT ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/046395 [patent_app_country] => US [patent_app_date] => 2019-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14993845 [patent_doc_number] => 20190315880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => HUMAN ANTIBODY DRUG CONJUGATES AGAINST TISSUE FACTOR [patent_app_type] => utility [patent_app_number] => 16/367933 [patent_app_country] => US [patent_app_date] => 2019-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34198 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16367933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778077 [patent_doc_number] => 20210115155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING LIGELIZUMAB [patent_app_type] => utility [patent_app_number] => 17/041291 [patent_app_country] => US [patent_app_date] => 2019-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17041291 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14567011 [patent_doc_number] => 20190211112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => Antibodies Against Tissue Factor Pathway Inhibitor [patent_app_type] => utility [patent_app_number] => 16/363327 [patent_app_country] => US [patent_app_date] => 2019-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37306 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16363327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16925321 [patent_doc_number] => 11046783 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-29 [patent_title] => Antibodies capable of binding to the coagulation factor XIa and uses thereof [patent_app_type] => utility [patent_app_number] => 16/292196 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 37 [patent_no_of_words] => 21893 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16292196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17407191 [patent_doc_number] => 11248060 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-15 [patent_title] => Antibodies that recognize red blood cell antigens [patent_app_type] => utility [patent_app_number] => 16/289268 [patent_app_country] => US [patent_app_date] => 2019-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 31 [patent_no_of_words] => 13760 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 207 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16289268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14403849 [patent_doc_number] => 20190167768 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) ASSOCIATED COAGULOPATHY, THROMBOCYTOPENIA, GLANZMANN'S THROMBASTHENIA, AND/OR THROMBOSIS [patent_app_type] => utility [patent_app_number] => 16/276769 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24221 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16276769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18028954 [patent_doc_number] => 11512127 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-29 [patent_title] => Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases [patent_app_type] => utility [patent_app_number] => 16/969774 [patent_app_country] => US [patent_app_date] => 2019-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 37 [patent_no_of_words] => 26103 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16969774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961630 [patent_doc_number] => 12331114 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Humanized anti-CD19 chimeric antigen receptor, its nucleic acid sequence and its preparation [patent_app_type] => utility [patent_app_number] => 16/969788 [patent_app_country] => US [patent_app_date] => 2019-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6197 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 294 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16969788 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15466201 [patent_doc_number] => 10548954 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-04 [patent_title] => Factor IX polypeptides and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/271689 [patent_app_country] => US [patent_app_date] => 2019-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 41 [patent_no_of_words] => 28154 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16271689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15538367 [patent_doc_number] => 10568943 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-25 [patent_title] => Factor IX polypeptides and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/271686 [patent_app_country] => US [patent_app_date] => 2019-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 41 [patent_no_of_words] => 28149 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16271686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14775063 [patent_doc_number] => 20190262429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/270302 [patent_app_country] => US [patent_app_date] => 2019-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24666 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16270302 [rel_patent_id] =>[rel_patent_doc_number] =>)